logo
Zacks Industry Outlook Highlights HSBC, ICICI Bank and Barclays

Zacks Industry Outlook Highlights HSBC, ICICI Bank and Barclays

Globe and Mail2 days ago

For Immediate Release
Chicago, IL – June 11, 2025 – Today, Zacks Equity Research discusses HSBC Holdings plc HSBC, ICICI Bank Ltd. IBN and Barclays PLC BCS.
Industry: Foreign Banks
Most banks across the globe have been continuously restructuring their businesses to focus on core operations. While these initiatives are expected to result in elevated expenses, they will drive growth in the long run. Though the uneven economic recovery in developed and emerging nations has been hurting revenue growth for companies within the Zacks Foreign Banks Industry, relatively lower interest rates will likely provide support.
Thus, despite geopolitical and macroeconomic woes, industry players like HSBC Holdings plc, ICICI Bank Ltd. and Barclays PLC are well-poised to gain from business streamlining efforts and relatively lower rates.
About the Industry
The Zacks Foreign Banks Industry consists of overseas banks with operations in the United States. Since a foreign banking organization may have federal and state-chartered offices in the country, the Federal Reserve plays a major role in supervising their U.S. operations.
In addition to providing a broad range of products and services to customers in the United States, the banks offer financial services to corporate clients having businesses in the country. The financial firms establish relations with U.S. corporations operating in their home countries.
Some units of foreign banks offer a broad range of wholesale and retail services and conduct money-market transactions for their parent organizations. Some industry players are involved in developing only specialized services like wealth/asset management and investment banking.
3 Themes Influencing the Foreign Banks Industry
Restructuring Efforts: Several foreign banks have continuously been undertaking business restructuring initiatives. Many banks have been divesting or closing non-core operations to increase focus on core businesses and profitable markets. Through this, industry players are changing their revenue mix and aiming to expand to other lucrative operations.
Relatively Lower Interest Rates: Given that inflation numbers are gradually cooling, central banks globally have started lowering interest rates. This is expected to support foreign banks' net interest income (NII) and margins, which were under pressure because of higher funding/deposit costs. With falling rates and decent economic growth, demand for loans is expected to improve. Industry players are likely to witness NII expansion.
Further, efforts taken by most banks to diversify revenues to become less dependent on spread income are likely to aid non-interest income. Also, lower interest rates will likely lead to the revival of investment banking business and support wealth/asset management operations. Hence, industry players are likely to record an increase in revenues in the coming quarters.
Uneven Global Economic Recovery: Following the COVID-19 pandemic, global economic recovery has been uneven. In many regions, economic growth has slowed but not fully recovered from the pandemic's effects, while geopolitical headwinds are hurting the economy in others. Banks' performances are directly linked to the performance of the overall economy. Weak economic growth in their home markets may hurt foreign banks' profitability to some extent in the upcoming period.
Zacks Industry Rank Indicates Bright Prospects
The Zacks Foreign Banks Industry is a 64-stock group within the broader Zacks Finance Sector. The industry currently carries a Zacks Industry Rank #14, which places it in the top 6% of more than 250 Zacks industries.
The group's Zacks Industry Rank, which is basically the average of the Zacks Rank of all the member stocks, indicates outperformance in the near term. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
The industry's positioning in the top 50% of the Zacks-ranked industries is because of the encouraging earnings outlook for the constituent companies in aggregate. The aggregate earnings estimate revisions show that analysts are gaining confidence in this group's growth potential. Since November 2024, the industry's earnings estimates for 2025 have been revised 11.3% upward.
Hence, we present a few stocks from the industry that you may want to keep an eye on. But before that, let us check out the industry's recent stock market performance and valuation picture.
Industry vs. S&P 500 & Sector
The Zacks Foreign Banks Industry has outperformed the S&P 500 and its sector in the past two years. Stocks in the industry have collectively surged 60.8%. The S&P 500 composite has rallied 38.8% and the Zacks Finance Sector has appreciated 45%.
Industry's Valuation
One might get a good sense of the industry's relative valuation by looking at its price-to-tangible book ratio (P/TBV), which is commonly used for valuing foreign banks because of large variations in their earnings results from one quarter to the next.
The industry currently has a trailing 12-month P/TBV of 2.34X. This compares with the highest level of 2.46X, the lowest level of 1.03X and the median of 1.69X over the past five years. The industry is trading at a significant discount compared with the market at large, as the trailing 12-month P/TBV for the S&P 500 composite is 12.80X, which the chart below shows.
As finance stocks typically have a lower P/TBV ratio, comparing foreign banks with the S&P 500 might not make sense to many investors. However, a comparison of the group's P/TBV ratio with that of its broader sector ensures that it is trading at a decent discount. The Zacks Finance Sector's trailing 12-month P/TBV of 5.33X and the median level of 4.68X for the same period are above the Zacks Foreign Banks Industry's ratios.
3 Foreign Bank Stocks to Consider
HSBC: Headquartered in London, HSBC is a major global banking and financial services firm with $3.05 trillion in assets as of March 31, 2025. The company has been committed to bolstering its performance, focusing on building operations across Asia. It intends to position itself as a top bank for high-net-worth and ultra-high-net-worth clients in the region.
In mainland China, HSBC has been growing its wealth business through lifestyle-focused centers, acquisitions like Citigroup's retail wealth arm, digital upgrades and talent hires. In India, the company is expanding rapidly, with approval to open 20 new branches, adding to its current 26. As the country's wealthy population surges, HSBC is boosting its presence through initiatives like launching Global Private Banking, acquiring L&T Investment Management and enhancing Premier Banking. These initiatives will likely help the company strengthen its position in the region.
Moreover, in sync with its Asia pivot strategy, HSBC announced plans to redeploy an additional $1.5 billion from the reallocation of costs from non-strategic or low-returning activities into its core strategy, wherein it has competitive strength. The bank is winding down its mergers and acquisitions, and equity capital markets operations in the U.K., Europe and the United States while maintaining a more focused presence in Asia and the Middle East.
It is also progressing with divestments in Germany, South Africa, Bahrain and France, and has begun a strategic review of its business in Malta. Apart from these, HSBC completed the sale of its businesses in the United States, Canada, New Zealand, Greece, Russia, Argentina and Armenia, as well as the retail banking operations in France and Mauritius.
Further, HSBC has been restructuring its operations to improve operating efficiency. In February 2025, the company announced a $1.5-billion cost-saving plan from the organizational simplification efforts (to be achieved by 2026). It will likely incur $1.8 billion in total severance and other upfront charges by the end of next year to implement these efforts.
Shares of the company have risen 24.4% on the NYSE in the past six months. The Zacks Consensus Estimate for its current-year earnings has moved marginally higher in the past 60 days. Currently, HSBC carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
ICICI Bank: Headquartered in Mumbai, India, ICICI Bank is one of India's largest private sector banks, with total assets worth INR21,182.39 billion ($247.8 billion) as of March 31, 2025.
The bank is making commendable progress in improving digital banking services for retail and corporate clients. IBN has been striving to provide superior end-to-end seamless digital services, personalized solutions and value-added features to enable data-driven cross-sell and up-sell opportunities. The increasing adoption of the bank's mobile banking app — iMobile Pay — is helping garner a solid market share. Apart from this, the company's digital platform for businesses has witnessed tremendous growth in the past few quarters.
These efforts are leading to a rapid increase in end-to-end digital sanctions and disbursements across various products.
Moreover, ICICI Bank has been leveraging its technological initiatives to augment the contribution of non-interest income toward its top line. The company has been continuing to enhance the use of technology in its operations to provide simplified solutions to customers. The company has introduced DigiEase, a digital platform designed to streamline the customer onboarding process for Business Banking. Further, iLens, the retail lending platform, is being upgraded on an ongoing basis, with retail credit cards now integrated into the platform along with mortgages, personal loans and education loans.
These digitization efforts have started bearing fruit, and non-interest income continues to improve. The metric increased 15.9% in fiscal 2025 and 15% in fiscal 2024, following a 13% rise in fiscal 2023 and 27% growth in fiscal 2022. Efforts to digitize operations and an increase in mobile banking transactions will likely continue to help the company garner more fee income.
Shares of this Zacks Ranked #3 company have risen 7.8% on the NYSE in the past six months. The Zacks Consensus Estimate for its current fiscal-year earnings has moved marginally lower in the past 60 days.
Barclays: Headquartered in London, Barclays is a major global banking and financial services company with £1,593.5 billion ($2,061.1 billion) in total assets as of March 31, 2025.
Barclays' initiatives to improve efficiency over the last few years have been bearing fruit, as evident by a fall in expenses. While total operating expenses increased in 2022, 2023 and the first quarter of 2025, the metric declined in 2024, with the negative compound annual growth rate (CAGR) being 2.4% over the six years ended 2021. Overall expenses are expected to be manageable as business restructuring initiatives continue to provide support.
The company intends to undertake further cost-saving actions to improve efficiency. Structural cost actions have resulted in gross savings of £1 billion in 2024 and £150 million in the first quarter of 2025. Barclays aims to achieve gross efficiency savings of £0.5 billion in 2025. By 2026-end, management expects total gross efficiency savings of £2 billion and the cost-to-income ratio to be in the high 50s.
Barclays has been striving to simplify operations and focus on its core businesses. In April 2025, it announced a collaboration with Brookfield to transform its payment acceptance business. In February 2025, it divested its Germany-based consumer finance business. In November 2024, the company acquired Tesco's retail banking business, which complement its existing business and strengthen its position in the market.
In 2024, it divested its Italian mortgage portfolio. The company sold $1.1 billion in credit card receivables to bolster the lending capacity for Barclays Bank Delaware in the United States. Driven by these initiatives, the company's profitability is expected to improve over time.
Currently, Barclays carries a Zacks Rank of 3. BCS shares have gained 32.8% on the NYSE in the past six months. The Zacks Consensus Estimate for the company's 2025 earnings has moved 6.2% higher in the past 60 days.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Barclays PLC (BCS): Free Stock Analysis Report
ICICI Bank Limited (IBN): Free Stock Analysis Report
HSBC Holdings plc (HSBC): Free Stock Analysis Report

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Prediction: Palantir Stock Will Plummet in the Second Half of 2025. The Reason Why Is Obvious.
Prediction: Palantir Stock Will Plummet in the Second Half of 2025. The Reason Why Is Obvious.

Globe and Mail

time2 hours ago

  • Globe and Mail

Prediction: Palantir Stock Will Plummet in the Second Half of 2025. The Reason Why Is Obvious.

Data mining specialist Palantir Technologies (NASDAQ: PLTR) picked up right where it left off in 2024. Last year, Palantir stock was the top performer in the S&P 500 index, as well as the third-best stock in the Nasdaq-100. So far in 2025, things haven't changed much for the artificial intelligence (AI) software player -- as shares have rocketed by an eye-popping 74% as of this writing (June 10). While the momentum doesn't appear to be slowing down at all for Palantir, my prediction is that the stock will plummet during the second half of the year. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Let's explore some of the trends fueling Palantir stock right now, as well as some interesting breadcrumbs that could support my idea that shares are headed for a sell-off. Should you dump your Palantir position right now? Read on to find out. Palantir's valuation is sky high, and... There is a lot that can be gathered from the chart below. The obvious takeaway is that Palantir's price-to-sales (P/S) multiple of 105 is significantly higher than any of the software growth stocks in this peer set. However, the bigger idea from the analysis below is that Palantir's valuation continues to expand. PLTR PS Ratio data by YCharts These dynamics imply that investors are buying Palantir stock in droves. The deeper question I've been asking is: Who are the investors that keep chasing Palantir's momentum? Based on some recent clues, I think I might have an answer. ...smart investors are taking profits Ark Invest CEO Cathie Wood is one of the original Palantir bulls on Wall Street. Shortly following the company's IPO in late 2020, Wood appeared on financial news programs on a regular basis -- constantly talking about her excitement around Palantir and the company's ability to disrupt legacy software providers. While this was a great source of indirect PR for Palantir, Wood shocked the investment world when she dumped her stake sometime in 2022. Following these moves, Wood started accumulating a position in Palantir stock once again in 2023. Per the graph in the prior section, Ark Invest's position in Palantir is sitting on a healthy profit considering shares now hover around all-time highs. Wood has taken note of these trends, and the famous tech investor is once again reducing her exposure to Palantir. Wood isn't the only notable personality on Wall Street that's choosing to take profits in Palantir, though. Billionaire investor Stanley Druckenmiller of the Duquesne Family Office completely exited Palantir during the first quarter, per the fund's most recent 13F filing. Similar to Wood, Druckenmiller has also been in and out of Palantir stock in recent years. I view the decision to reduce exposure to Palantir stock right now as a prudent one. While the selling from Wood and Druckenmiller does not necessarily imply a bearish view of Palantir at all, I think trimming exposure and taking profits in a stock that seems overbought makes sense. My prediction is that more institutions will follow in the second half of 2025 Palantir's valuation is historically high, even compared to what investors witnessed during the peak bubble days of the dot-com boom. I think a rising number of institutions will come to the opinion that Palantir's current valuation trajectory is not sustainable given how far the stock has already run. PLTR Shares Increased by Institutional Investors data by YCharts The graph above illustrates the number of shares of Palantir stock that have increased and decreased by institutional investors over the last year. As the trends indicate, there was pronounced institutional buying of Palantir stock during the last few months of 2024. At the same time, the orange line -- which indicates institutional selling -- also steadily climbed during late 2024 and ultimately converged with the purple line (buyers) at the start of 2025. Right now, shares bought by institutions remains higher than shares sold, which implies large investors are net buyers of Palantir stock for the time being. Throughout this year, both buying and selling activity has decelerated -- as indicated by the relative flattening of both lines. These trends suggest that while institutions remain cautiously optimistic about Palantir, there could be further selling on the horizon as the narrowing gap between buyers and sellers becomes more obvious. As such, I think the current momentum fueling Palantir stock could tempt more institutions to dump their shares -- leading to a plummeting share price and much-needed valuation normalization. Ultimately, I don't think dumping your position in Palantir is entirely necessary. As a long-term investor, it's important to hold on to your highest-conviction winners. However, I do think taking some gains off the table could be a smart decision right now. Should you invest $1,000 in Palantir Technologies right now? Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $657,871!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $875,479!* Now, it's worth noting Stock Advisor 's total average return is998% — a market-crushing outperformance compared to174%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025

NASH Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 80+ Companies and 80+ Therapies
NASH Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 80+ Companies and 80+ Therapies

Globe and Mail

time6 hours ago

  • Globe and Mail

NASH Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 80+ Companies and 80+ Therapies

DelveInsight's, 'Nonalcoholic Steatohepatitis Pipeline Insight, 2025' report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Nonalcoholic Steatohepatitis pipeline landscape. It covers the NASH Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NASH Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the NASH Pipeline. Dive into DelveInsight's comprehensive report today! @ NASH Pipeline Outlook Key Takeaways from the NASH Pipeline Report In May 2025, Novo Nordisk A/S announced a study will last for about 5 years. Participants will have up to 21 clinic visits and 9 phone calls with the clinical staff during the study. Some of the clinic visits may be spread over more than one day. Participants with other chronic liver diseases cannot take part in this study. Women cannot take part in the study if they are pregnant, breast-feeding or plan to become pregnant during the study period. In May 2025, Akero Therapeutics Inc. conducted a phase 2b study Evaluating the Safety and Efficacy of Efruxifermin in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH). DelveInsight's NASH Pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for NASH treatment. The leading NASH Companies such as Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics and others. Promising NASH Pipeline Therapies such as Semaglutide, HEC96719, DA-1241, Sitagliptin, Saroglitazar Magnesium 2mg, Vonafexor, PF-06835919, BMS-986036 and others. Stay ahead with the most recent pipeline outlook for NASH. Get insights into clinical trials, emerging therapies, and leading companies with NASH@ NASH Treatment Drugs NASH Emerging Drugs Profile Lanifibranor: Inventiva Pharma Lanifibranor, Inventiva's lead product candidate, is an orally-available small molecule that acts to induce antifibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor (PPAR) isoforms, which are well-characterized nuclear receptor proteins that regulate gene expression. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARδ, and a partial activation of PPARγ. While other PPAR agonists target only one or two PPAR isoforms for activation. The FDA has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of NASH. Currently, the drug is in Phase III stage of its clinical trial for the treatment of NASH. MSDC-0602K: Cirius Therapeutics MSDC-0602K, a second-generation oral insulin sensitizer, is designed to selectively modulate the mitochondrial pyruvate carrier (MPC) while minimizing direct PPAR-gamma activation. The MPC mediates at the cellular level the effects of over nutrition, a major cause of Nonalcoholic fatty liver disease NAFLD/NASH and Type 2 diabetes. In preclinical studies, modulation of the MPC has been shown to improve insulin sensitivity, lipid metabolism, and inflammation. Currently the drug is in Phase III stage of Clinical trial for the treatment of NASH. TERN-501 is a THR-β agonist with high metabolic stability, enhanced liver distribution and greater selectivity for THR-β compared to other THR-β agonists in development. Agonism of THR-β increases fatty acid metabolism via mitochondrial oxidation and affects cholesterol synthesis and metabolism. As a result, THR-β stimulation has the ability to reduce hepatic steatosis and improve serum lipid parameters including LDL cholesterol and triglycerides. In vivo NASH studies in a rodent model have demonstrated that low-doses of TERN-501 achieved complete resolution of steatosis and reductions in serum lipids, hepatic inflammation and fibrosis. TERN-501 has high liver distribution and is 23-fold more selective for THR-β than for THR-α activation in a cell free assay, thereby minimizing the risk of cardiotoxicity and other off-target effects associated with non-selective THR stimulation. Currently, the drug is in Phase II stage of its clinical trial for the treatment of NASH. HTD 1801: HighTide Biopharma The company's lead drug candidate, HTD1801, is a first-in-class new molecular entity (ionic salt of two active moieties). It is a novel orally active ionic salt of berberine and ursodeoxycholic acid, substantially reduced liver fat while improving glycemic control and other cardiometabolic biomarkers in adults with nonalcoholic steatohepatitis (NASH) and type 2 diabetes (T2DM). Currently, it is in Phase II trials for the treatment of primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH). The NASH Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of NASH with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for NASH Treatment. NASH Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. NASH Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the NASH market Explore groundbreaking therapies and clinical trials in the NASH Pipeline. Access DelveInsight's detailed report now! @ New NASH Drugs NASH Companies Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics and others. Nonalcoholic Steatohepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical NASH Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Unveil the future of NASH Treatment. Learn about new drugs, NASH Pipeline developments, and key companies with DelveInsight's expert analysis @ NASH Market Drivers and Barriers Scope of the NASH Pipeline Report Coverage- Global NASH Companies- Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics and others. NASH Pipeline Therapies- Semaglutide, HEC96719, DA-1241, Sitagliptin, Saroglitazar Magnesium 2mg, Vonafexor, PF-06835919, BMS-986036 and others. NASH Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination NASH Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on NASH Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ NASH Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary Nonalcoholic Steatohepatitis: Overview Pipeline Therapeutics Therapeutic Assessment Nonalcoholic Steatohepatitis– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Lanifibranor: Inventiva Pharma Drug profiles in the detailed report….. Mid Stage Products (Phase II) TERN-501: Terns Pharmaceuticals Drug profiles in the detailed report….. Early Stage Products (Phase I) LY3849891: Eli Lilly and Company Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name : Company name Drug profiles in the detailed report….. Inactive Products Nonalcoholic Steatohepatitis Key Companies Nonalcoholic Steatohepatitis Key Products Nonalcoholic Steatohepatitis- Unmet Needs Nonalcoholic Steatohepatitis- Market Drivers and Barriers Nonalcoholic Steatohepatitis- Future Perspectives and Conclusion Nonalcoholic Steatohepatitis Analyst Views Nonalcoholic Steatohepatitis Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:

Health Data Interoperability Market to Hit US$352.13 Billion by 2032 with 22.65% CAGR
Health Data Interoperability Market to Hit US$352.13 Billion by 2032 with 22.65% CAGR

Globe and Mail

time7 hours ago

  • Globe and Mail

Health Data Interoperability Market to Hit US$352.13 Billion by 2032 with 22.65% CAGR

According to a recent report by Coherent Market Insights, the global Health Data Interoperability Market is estimated to be valued at USD 84.58 billion in 2025 and is expected to reach USD 352.13 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 22.65% from 2025 to 2032. The strong growth of the market is driven by the rising demand for seamless data exchange among healthcare providers, the pursuit of enhanced patient care, and the growing adoption of electronic health records (EHRs) and other digital health technologies. Global Health Data Interoperability Market Key Takeaways According to Coherent Market Insights (CMI), the global health data operability care market size is projected to grow more than 4.1X, increasing from USD 84.58 Bn in 2025 to USD 352.13 Bn by 2032, at a CAGR of 22.65%. By deployment model, cloud-based segment is expected to account for nearly two-thirds of the global health data interoperability market share in 2025. Based on component, software category is anticipated to generate a market revenue of about USD 45.92 Bn in 2025. By type, electronic health records (EHRs) segment will likely account for more than two-fifths of the global market revenue share by 2025. North America is expected to retain its monopoly in the global market due to increasing adoption of digital health technologies. As per Coherent Market Insights' latest health data interoperability market research, North America will hold nearly 2/5 of the global market share in 2025. Asia Pacific health data interoperability market is estimated to be valued at around USD 25.62 Bn in 2025. Growing Adoption of Electronic Health Records (EHRs) Boosting Market Growth Coherent Market Insights' new health data interoperability market analysis offers insights into prominent factors driving industry growth. Increasing adoption of electronic health records (EHRs) is one key growth driver. In the contemporary world, more and more hospitals and clinics are embracing electronic health records. For instance, as per the National Center for Health Statistics, about 88.2% of office-based physicians in the United States use an EMR/EHR system. High adoption of EHRs is creating an urgent need for seamless data exchange across various healthcare systems. This will drive demand for health data interoperability solutions during the forecast period. High Implementation Cost and Lack of Standardization Limiting Market Growth The future health data interoperability market outlook looks promising. However, lack of universal standards and high implementation costs are expected to restrain market growth to some extent. Different healthcare providers often use disparate EHR systems, making seamless data exchange challenging. Absence of universally accepted interoperability standards across regions can hinder consistent integration and data sharing, negatively affecting the health data interoperability market growth. Implementing interoperable systems requires substantial investments in both infrastructure and software. This deters smaller clinics and healthcare providers, especially across underserved regions, from opting for these systems, thereby reducing the health data interoperability market demand. Purchase Now Up to 25% Discount on This Premium Research Report: Rapid Shift Towards Value-Based Care to Create Lucrative Growth Avenues Growing adoption of value-based care (VBC) models is driving demand for improved patient outcomes and cost efficiency across healthcare systems. This transition necessitates seamless health data interoperability to enable coordinated care as well as real-time data exchange and performance measurement. As a result, the shift towards VBC is unlocking significant growth opportunities for health data interoperability companies. Policies like HITECH Act and EU GDPR mandate interoperability as well as patient access to data. They will also create lucrative growth prospects for health data interoperability solution providers in the coming years. Policies like the HITECH Act and the EU GDPR emphasize interoperability as well as patient access to health data. These regulations are expected to drive demand for health data interoperability solutions, creating lucrative growth opportunities for industry players. Impact of AI on the Health Data Interoperability Market AI is revolutionizing the health data interoperability industry by tackling long-standing challenges like fragmented data and inconsistent data standards. Organizations use machine learning and NLP to automate data mapping, convert unstructured records into structured formats, and streamline EHR integration. AI-driven predictive analytics can forecast data exchange needs, enhance real‑time clinical workflows, and reduce clinical errors. Federated learning frameworks allow AI models to train across multiple organizations without moving sensitive patient data, which improves privacy and fosters collaboration. AI-powered interoperability solutions are gaining immense traction in the modern healthcare ecosystem. This is due to their potential to boost operational efficiency, enable personalized care, reduce costs, and accelerate the transition towards value‑based models. Emerging Health Data Interoperability Market Trends Rising demand for patient-centric care is a key growth-shaping trend in the market. Today, patients want access to their health information through mobile apps and patient portals. This is creating a need for connected systems. Growing popularity of cloud-based interoperability solutions is expected to boost the overall health data interoperability market value. These scalable and cost-effective platforms are gradually replacing on-premise systems across various regions. Rise of telehealth services and adoption of remote patient monitoring devices are also positively impacting the health data interoperability market growth. These technologies require robust interoperability solutions to ensure seamless data flow between patients, healthcare providers, and monitoring platforms. Analyst's View 'The global health data interoperability market is poised to exhibit robust growth, owing to increasing government mandates and regulatory frameworks, widespread adoption of electronic health and medical record systems (EHR/EMR), and a growing emphasis on value-based care models,' said senior analyst Komal Dighe. Current Events and Their Impact on the Health Data Interoperability Market Event Description and Impact U.S. HTI-1 Final Rule Description: U.S. HTI-1 Final Rule enforces FHIR-based standards for certified health IT systems. Impact: This drives adoption of compliant interoperability platforms and APIs, leading to market growth. EU's European Health Data Space (EHDS) Rollout Description: European Union's EHDS initiative, officially implemented in 2025, requires member states to adopt standardized cross-border health data sharing through unified interoperability frameworks. Impact: This is driving health IT vendors to comply with EHDS standards as well as boosting demand for FHIR-based platforms and multilingual data exchange solutions. Competitor Insights Key companies in health data interoperability market report include: - Cerner Corporation - Epic Systems Corporation - Meditech - Allscripts Healthcare Solutions - athenahealth - InterSystems Corporation - Philips Healthcare - GE Healthcare - Oracle Health Sciences - NextGen Healthcare - IBM Watson Health - Microsoft Health - McKesson Corporation - Siemens Healthineers - Infor Healthcare Key Developments In March 2025, 1upHealth sets a new benchmark for health data interoperability with the launch of its new 1up Platform. The new platform, built on a modern lakehouse architecture, is designed to deliver 'Health Data On Demand'. It offers real-time data access, scalable management, and advanced analytics to help healthcare organizations enhance operational efficiency, care quality, and patient outcomes. In March 2025, Epic Systems Corporation unveiled industry-leading Genomics, AI, and interoperability solutions at the HIMSS 2025 Conference. These new solutions are designed to help healthcare organizations advance in rapidly evolving environment. They have the potential to enhance clinical care, streamline operations, and foster more personalized patient treatments. In January 2025, MEDITECH unveiled its new set of APIs fully compatible with version 4 of the United States Core Data for Interoperability (USCDI v4). This new launch highlights the company's leadership in advancing standards-based interoperability across healthcare systems. Market Segmentation Deployment Model Insights Cloud-Based On-Premises Component Insights Hardware Software Services Type Insights Electronic Health Records (EHR) Health Information Exchange (HIE) Interoperability Solutions Integration Platforms Interoperability Level Insights Foundational Interoperability Structural Interoperability Semantic Interoperability End User Insights Healthcare Providers Healthcare Payers Pharmaceutical Companies Research Institutions Regional Insights North America U.S. Canada Latin America Brazil Argentina Mexico Rest of Latin America Europe Germany U.K. Spain France Italy Russia Rest of Europe Asia Pacific China India Japan Australia South Korea ASEAN Rest of Asia Pacific Middle East GCC Countries Israel Rest of Middle East Africa South Africa North Africa § Central Africa Get Customization on this Report: About Us: Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries. Media Contact Company Name: Coherent Market Insights Contact Person: Mr. Raj Shah Email: Send Email Phone: +1-252-477-1362 Address: 533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States City: Burlingame State: California Country: United States Website:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store